Pharmaceutical - Vertex


Current filters:


Popular Filters

Report: Global cystic fibrosis market value to treble by 2019


The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

Vertex reports fifth consecutive quarter of losses; updates on Kalydeco


US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) has reported second quarter revenues of $311 million,…

FinancialIncivekIncivoKalydecoNorth AmericaPharmaceuticalVertex

Vertex slumps as FDA delays hepatitis C trial


US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Vertex and Bristol-Myers to trial VX-135 and daclatasvir for hep C; B-MS names new R&D head


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has entered into a non-exclusive agreement with pharma…

Anti-viralsBristol-Myers SquibbdaclatasvirManagementPharmaceuticalResearchVertexVX-135

Vertex receives first two Breakthrough Therapy Designations from US FDA


During its presentation at the JP Morgan annual health care conference, US drugmaker Vertex Pharmaceuticals…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertexVX-809

Vertex' hep C drug Incivek to carry boxed warning in USA; UK to fund Kalydeco


US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) says that the label on its new hepatitis C drug Incivek…

Anti-viralsEuropeIncivekKalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra


Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Canadian scientists' insights into Kalydeco for a rare form of cystic fibrosis


Scientists at the Hospital for Sick Children in Toronto, Canada, have established that a drug recently…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-770

FDA warns on possible cataract risk with Vertex' Kalydeco


The US Food and Drug Administration this week notified health care professionals, parents/caregivers…

KalydecoNorth AmericaPharmaceuticalRare diseasesRegulationVertex

EU approval for Eisai's epilepsy drug Fycompa and Vertex' Kalydeco


Japanese drug major Eisai (TYO: 4523) says that the European Commission has approved for marketing its…

EisaiEuropeFycompaKalydecoNeurologicalPharmaceuticalRare diseasesRegulationVertex

Vertex tumbles despite good final data on combo cystic fibrosis therapy


USA-based Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares tumble 16% to $51.18 last week, after…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertexVX-809

Incivek and Victrelis important advances in HCV, but still unmet needs


Nearly two-thirds of US surveyed physicians have seen an increase in the hepatitis C (HCV) patients they…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Vertex slumps as firm revises Kalydeco data


The USA's Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares plunge 19% to $52.85 in early trading…

KalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

EMA recommends approval of Vertex' CF drug Kalydeco


European Medicines Agency last Friday recommended approval of Kalydeco (ivacaftor), an orphan-designated…

EuropeKalydecoPharmaceuticalRare diseasesRegulationRespiratory and PulmonaryVertex

Incivek versus Victrelis in hepatitis C virus treatment: US physician views


For the treatment of hepatitis C virus (HCV), the majority of surveyed US physicians survey by advisory…

Anti-viralsIncivekMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRocheVertexVictrelis

Back to top